Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 19/20 | 0.83 |
| ▸ | PLA2G1B | P04054 | 7/20 | 0.83 |
| ▸ | PLA2G10 | O15496 | 5/20 | 0.83 |
| ▸ | PLA2G5 | P39877 | 4/20 | 0.83 |
| ▸ | PLA2G2E | Q9NZK7 | 4/20 | 0.83 |
| ▸ | PLA2G2F | Q9BZM2 | 2/20 | 0.64 |
| ▸ | PLA2G2D | Q9UNK4 | 2/20 | 0.64 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.64 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.64 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.64 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.64 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14531294 | 0.91 | PLA2G2A (0.88) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL819141 | 0.91 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL6694841 | 0.90 | PLA2G2A (0.98) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL6694834 | 0.90 | PLA2G2A (0.98) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| Varespladib SCHEMBL1232548 | 0.88 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| Varespladib SCHEMBL29430154 | 0.88 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818556 | 0.88 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL4652248 | 0.87 | PLA2G2A (0.81) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL819886 | 0.86 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818631 | 0.86 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | PLA2G2A 24/4885PLA2G1B 9/4885PLA2G10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.